Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Theravance Biopharma (TBPH) Misses Q1 EPS by 23c
May 5, 2022 5:22 PM EDTTheravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.34), $0.23 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $14.48 million.
Cash, cash equivalents and marketable securities totaled $147.5 million as of March 31, 2022.
For earnings history and... More
